Latest News

Previously approved for patients aged 12 and older, younger patients now have a treatment option to manage sudden hereditary angioedema attacks.

FDA approves zoliflodacin, a groundbreaking oral treatment for gonorrhea, offering hope against antibiotic resistance and improving patient access.

Measles cases surge in the US, prompting quarantine measures in South Carolina schools and raising urgent vaccination concerns amid declining rates.

FDA grants a national priority voucher to teclistamab and daratumumab for relapsed/refractory multiple myeloma, enhancing treatment approval speed.

Second-line and later treatment options for synovial sarcoma are limited. Afamitresgene autoleucel is the first FDA-approved T-cell receptor therapy, demonstrating long-lasting responses and tolerable adverse effects in pretreated patients.

Nonadherence has negative impacts on patients, health systems, and society.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

Thyroid Diseases Can Have Widespread Physiological Effects

Retatrutide shows promising results in reducing weight and knee pain for individuals with obesity and osteoarthritis, enhancing physical function significantly.

The FDA has approved etripamil as the first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia (PSVT), offering a rapid, effective treatment that can be used outside of health care settings.

Pharmacists play a vital role in modern clinical trials, enhancing patient safety and trial efficiency through drug management and protocol development.

Lerodalcibep, a new PCSK9 inhibitor, offers a convenient monthly injection to effectively lower LDL cholesterol in patients with hypercholesterolemia.

Pharmacy leaders at ASHP Midyear 2025 highlight urgent concerns about future uncertainties and preparedness for crises impacting health systems and patient care.

Research reveals that isatuximab on-body injector shows consistent safety and efficacy across various body weight groups in multiple myeloma treatment.

SABCS 2025 showcases breakthroughs in breast cancer therapy, emphasizing novel therapies and precision medicine to enhance patient outcomes.

Pivotal FDA approvals in breast cancer treatment focused on precision medicine and innovative therapies in 2025.

Pharmacists enhance oncology care by guiding younger patients through precision diagnostics like ctDNA MRD testing, driving innovation in cancer treatment.

The FDA has approved a new combination therapy for BRCA2-mutated metastatic prostate cancer, showing significant efficacy in clinical trials.

Exploratory findings from the MONALEESA-3 trial presented at SABCS 2025 show ribociclib plus fulvestrant significantly enhances survival in ILC.

Discover how antibody drug conjugates (ADCs) are transforming treatment for HER2-positive breast cancer with brain metastases at SABCS 2025.